SAN DIEGO and PENNINGTON, N.J., Nov.
8, 2018 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer
immunotherapies, today announced the appointment of Robert Ward to its Board of Directors. Mr.
Ward is currently Chairman and Chief Executive Officer of Eloxx
Pharmaceuticals.
"It is with great pleasure that we welcome Bob to our
Board. His considerable industry experience leading
pharmaceutical companies in bringing new therapies to market and
deep insight into successful commercialization strategies will be
extremely valuable to OncoSec as we continue to advance
our TAVO™ platform," said Avtar
Dhillon, Chairman of OncoSec.
Mr. Ward brings to OncoSec over 30 years of experience as a
global biopharmaceutical industry leader with experience across the
full spectrum of drug development and commercialization. Mr.
Ward currently serves as Chairman and Chief Executive Officer of
Eloxx Pharmaceuticals. Prior to joining Eloxx, Mr. Ward was
President and Chief Executive Officer of Radius Health, Inc., where
he helped the company successfully complete its initial public
offering and lead the development, approval and launch of the
company's TYMLOS™ injection. Prior to joining Radius, Mr.
Ward was Vice President for Strategy and External Alliances for the
New Opportunities iMed of Astra Zeneca. He has held a series
of progressive management and executive roles with established
companies such as NPS Pharmaceuticals, Schering-Plough (Merck),
Pharmacia (Pfizer), Bristol-Myers Squibb and Genentech. Mr. Ward
currently serves as a Director of the Massachusetts High Technology
Council and had served as a Director of Akari Therapeutics from
October 2016 to August 2018.
Mr. Ward received a B.A. in Biology and a B.S. in Physiological
Psychology, both from the University of
California, Santa Barbara, an M.S. in Management from the
New Jersey Institute of Technology and
an M.A. in Immunology from the John Hopkins University School of
Medicine.
About OncoSec Medical Incorporated
OncoSec is a clinical-stage biotechnology company focused on
developing cytokine-based intratumoral immunotherapies to stimulate
the body's immune system to target and attack cancer.
OncoSec's lead immunotherapy platform – TAVO™ (tavokinogene
telseplasmid) – enables the intratumoral delivery of DNA-based
interleukin-12 (IL-12), a naturally occurring protein with
immune-stimulating functions. The technology, which employs
electroporation, is designed to produce a controlled, localized
expression of IL-12 in the tumor microenvironment, enabling the
immune system to target and attack tumors throughout the body.
OncoSec has built a deep and diverse clinical pipeline
utilizing TAVO™ as a potential treatment for multiple cancer
indications either as a monotherapy or in combination with leading
checkpoint inhibitors; with the latter potentially enabling OncoSec
to address a great unmet medical need in oncology: anti-PD-1
non-responders. Results from recently completed clinical
studies of TAVO™ have demonstrated a local immune response, and
subsequently, a systemic effect as either a monotherapy or
combination treatment approach. In addition to TAVO™, OncoSec
is identifying and developing new DNA-encoded therapeutic
candidates and tumor indications for use with its ImmunoPulse®
platform. For more information, please visit
www.oncosec.com.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
David Schemelia/ Jason Rando
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
dschemelia@tiberend.com
jrando@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-appoints-robert-ward-to-its-board-of-directors-300746576.html
SOURCE OncoSec Medical Incorporated